SynthesisJournal of gastrointestinal cancer2026
Incidence, Risk Factors, and Management of Radiotherapy-Related Skin Toxicity in Rectoanal Cancer Patients: a Systematic Review and Meta-Analysis.
Synthesis in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy is essential for rectoanal cancer, but pelvic anatomy and high radiation doses increase radiodermatitis risk, potentially compromising treatment efficacy. No specific meta-analysis exists for this group.
methodsWe systematically searched PubMed, Embase, Cochrane Library, and Web of Science up to September 2025. Pooled meta-analysis, network meta-analysis, and dose-effect meta-analysis were performed on 50 included studies (n = 4,892).
resultsThe overall radiodermatitis incidence was 58.7% (95% CI: 55.2%-62.1%), including severe (Grade ≥ 3, 12.3%) and moist desquamation (34.5%). Key independent risk factors (P < 0.05) were tumor distance ≤ 5 cm from anal verge (OR = 2.86), stoma absence (OR = 3.12), total dose > 50 Gy (OR = 2.59), concurrent chemotherapy (OR = 2.73), HIV infection (OR = 5.82), 3D-CRT vs. IMRT (OR = 8.76), and tumor skin invasion (OR = 36.0). Effective interventions included spray-type skin protectants (SUCRA = 92.3%), volumetric modulated arc therapy (VMAT; OR = 0.29 vs. 3D-CRT), recombinant human epidermal growth factor, and amifostine. A dose inflection point occurred at 50 Gy, with a 29% increased risk of severe dermatitis per additional 5 Gy above this threshold.
conclusionsSkin toxicity is common in rectoanal cancer radiotherapy and linked to tumor, treatment, and patient factors. Optimized techniques (e.g., VMAT) combined with spray-type protectants enable precision management, improving outcomes.
Indexed as
Identifiers
41538092What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.